Pharma Industry
Industry: Email Alert RSS FeedHemoBioTech announces filing of patent application for blood loss treatment.
BIOTECH Patent News, May, 2006
HemoBioTech, Inc. (Dallas, TX) said that Texas Tech University filed a patent application for induction of erythropoiesis (red blood cell production) by HemoTech, a novel chemically modified hemoglobin. HemoBioTech has a worldwide exclusive license to HemoTech, which is being developed as a blood substitute.
"We are very excited about the erythropoietic property of HemoTech," said Dr. Arthur P. Bollon, Chairman and CEO of HemoBioTech. "There is a strong interest in new agents which increase the level of red blood cells in patients. The development of a blood substitute that not only carries oxygen, but also increases the level of red blood cells, could have broad applications in medicine, especially trauma, elective surgery, acute anemia, cancer and heart...
- How to choose the right insurance carrier for your business
- Real Estate: Prepare your properties to weather what lies ahead
- Technology: Be prepared if part of your global supply chain goes missing
Most Recent Technology Articles
- INTERVIEW WITH BEN BUTTERS, DIRECTOR OF EUROPEAN AFFAIRS AT EUROCHAMBRES : "A PERFECT ROAD MAP FOR EU CLUSTERS DOES NOT EXIST".
- AGENDA.(Brief article)(Conference notes)
- FIGHT AGAINST INTERNET PIRACY.
- INTERNET : AUTHORS' SOCIETIES URGE ACTION AGAINST PIRACY.
- TELECOMMUNICATIONS : BUSINESSEUROPE HOSTILE TO FURTHER CONTRACTUAL OBLIGATIONS.(Brief article)
Most Recent Technology Publications
Most Popular Technology Articles
- 3G: naughty or nice? PhoneErotica.com generates over 300 million hits per month, and rings up more minutes of use per month than MSN
- Business process re-engineering in the small firm: A case study
- Performance analysis of shell and tube heat exchanger using miscible system
- What is precision air conditioning and why is it necessary?
- Optimizing of Trichoderma viride cultivation in submerged state fermentation


